Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Nature communications·2026
Same author

Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Cancer immunology research·2026
Same author

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

Nature cancer·2026
Same author

Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma.

Blood cancer discovery·2025
Same authorSame journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same authorSame journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Jul 1, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Cellular immunotherapy for multiple myeloma.

Jacalyn Rosenblatt1, David Avigan

  • 1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Best Practice & Research. Clinical Haematology
|September 16, 2008
PubMed
Summary
This summary is machine-generated.

Immunotherapy offers a promising new avenue for treating multiple myeloma, a blood cancer where standard treatments often fail. Strategies like vaccination and monoclonal antibodies aim to selectively target cancer cells, improving patient outcomes.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Related Experiment Videos

Last Updated: Jul 1, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Multiple myeloma is a serious hematological malignancy with inadequate standard therapies.
  • Current treatments like autologous stem cell transplantation achieve cytoreduction but lead to relapse due to chemotherapy-resistant disease.
  • Allogeneic transplantation offers durable responses via anti-tumor immunity but faces challenges with graft-vs-host disease.

Purpose of the Study:

  • To explore novel immunotherapeutic approaches for selective targeting and elimination of multiple myeloma cells.
  • To review current advancements in immunotherapy for multiple myeloma, including vaccination and monoclonal antibody strategies.
  • To identify strategies for overcoming limitations in immunotherapy efficacy, such as effector cell dysfunction and regulatory T cells.

Main Methods:

  • Identification of tumor-associated antigens for targeted immunotherapy.
  • Development of vaccination strategies (single antigen and whole-cell approaches).
  • Evaluation of monoclonal antibodies in preclinical and clinical studies.
  • Investigation of methods to enhance immunotherapy, including T regulatory cell depletion and combination therapies.

Main Results:

  • Tumor-associated antigens have been identified for selective targeting in multiple myeloma.
  • Vaccination strategies and monoclonal antibodies show promise in clinical and preclinical studies.
  • Effector cell dysfunction and increased regulatory T cells can limit immunotherapy efficacy.

Conclusions:

  • Immunotherapy presents a promising strategy for treating multiple myeloma by selectively targeting cancer cells.
  • Strategies to enhance immunotherapy, such as T regulatory cell depletion and combination approaches, are crucial for improving patient outcomes.
  • Combining immunotherapy with autologous or allogeneic transplantation may offer synergistic benefits for durable responses in multiple myeloma.